<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816721</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 938-201</org_study_id>
    <nct_id>NCT04816721</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate EDP 938 Regimens in Children With RSV</brief_title>
  <acronym>RSVPEDs</acronym>
  <official_title>A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 36 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children&#xD;
      with RSV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, dose ranging, placebo-controlled study in respiratory&#xD;
      syncytial virus (RSV) among hospitalized and non-hospitalized children aged from 28 days to&#xD;
      36 months, assessing the safety, tolerability, pharmacokinetics, clinical outcome and&#xD;
      antiviral activity of a 5 day treatment with EDP-938.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of EDP-938 (Part 1)</measure>
    <time_frame>Up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Predose concentration of EDP-938 (Part 1)</measure>
    <time_frame>Up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of EDP-938 compared to placebo measured by adverse events (Part 1)</measure>
    <time_frame>Up to 29 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily change from baseline in RSV shedding (Part 2)</measure>
    <time_frame>Up to 14 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC for RSV RNA viral load (Part 1 and Part 2)</measure>
    <time_frame>Up to 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily change in RSV shedding (Part 1)</measure>
    <time_frame>Up to 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with undetectable level of RSV RNA viral load (Part 1 and Part 2)</measure>
    <time_frame>Up to 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to RSV RNA viral load being undetectable (Part 1 and Part 2)</measure>
    <time_frame>Up to 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-938 (Part 2)</measure>
    <time_frame>Up to 5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose concentration of EDP-938 (Part 2)</measure>
    <time_frame>Up to 5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of EDP-938 compared to placebo measured by adverse events (Part 2)</measure>
    <time_frame>Up to 29 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <arm_group>
    <arm_group_label>EDP-938</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-938, oral suspension, once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938</intervention_name>
    <description>Oral suspension</description>
    <arm_group_label>EDP-938</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral suspension to match EDP-938</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female who is either: born ≥37 weeks of gestation and is age ≥28 days to ≤36&#xD;
             months, defined at the time of randomization, or born &lt;37 weeks of gestation and is&#xD;
             age ≥6 months to ≤36 months defined at the time of randomization&#xD;
&#xD;
          -  Subjects diagnosed with RSV infection&#xD;
&#xD;
          -  Subjects with signs of an acute respiratory illness with onset ≤72 hours (for&#xD;
             hospitalized subjects) and ≤48 hours (non hospitalized subjects) before the time of&#xD;
             signing the ICF&#xD;
&#xD;
          -  In the Investigator's opinion, the subject's caregiver understands and is able to&#xD;
             comply with protocol requirements, instructions, and protocol-stated restrictions, and&#xD;
             the subject is likely to complete the study as planned&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of or anticipated need for intensive monitoring and associated medical care&#xD;
&#xD;
          -  Underlying immune deficiency, eg, from confirmed human immunodeficiency virus&#xD;
             infection or use of an immunosuppressive medication except immunoglobulin A deficiency&#xD;
&#xD;
          -  Receipt of (within 12 months before Screening) or on a waiting list for a bone marrow,&#xD;
             stem cell, or solid organ transplant, or who received radiation or chemotherapy&#xD;
             (within 12 months before screening)&#xD;
&#xD;
          -  Receiving chronic oxygen therapy at home before admission&#xD;
&#xD;
          -  Receiving an investigational or approved medication that is intended to prevent or&#xD;
             treat RSV infection within 30 days or 5 half-lives (whichever is longer) before the&#xD;
             first dose of study drug, and/or is currently enrolled in a clinical trial of such a&#xD;
             medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <phone>857 760 0548</phone>
    <email>gdelarosa@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Care Miller Children's and Women's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Children's Research Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LSU Health</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of the Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <zip>2093</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus, RSV, Pediatric study</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

